Clinical and economic assessment of using IRS®19 for the treatment and prevention of acute respiratory infections in children
Objective: to perform pharmacoeconomic analysis of the feasibility of using topical bacterial lysate in the form of nasal spray (IRS®19) for the treatment and prevention of upper respiratory tract infections in pediatric population in comparison with other drugs registered in Russia, belonging to th...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2024-08-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/1036 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849394855301611520 |
|---|---|
| author | A. S. Kolbin A. R. Kasimova |
| author_facet | A. S. Kolbin A. R. Kasimova |
| author_sort | A. S. Kolbin |
| collection | DOAJ |
| description | Objective: to perform pharmacoeconomic analysis of the feasibility of using topical bacterial lysate in the form of nasal spray (IRS®19) for the treatment and prevention of upper respiratory tract infections in pediatric population in comparison with other drugs registered in Russia, belonging to the class of topical interferons.Material and methods. Based on the Rosstat data and information from open sources, the population of patients with acute respiratory infections (ARI) was calculated. Considering the Russian clinical recommendations “Acute respiratory viral infection (ARVI)” and “Acute tonsillitis and pharyngitis (acute tonsillopharyngitis)”, the direct medical costs of providing medical care to specialized patients were determined. Direct costs on the part of parents included all costs for purchasing medicines for basic or concomitant therapy. Direct costs on the part of the healthcare system and the state included the costs of providing medical care at the outpatient stage. Direct non-medical costs included payments for disability leaves, indirect costs – lost gross domestic product (GDP) due to absence from work.Results. The total costs of the healthcare system and the state for 1 AVI patient are 42,472 rubles in case of uncomplicated course and 70,649 rubles in case of complicated course. In case of IRS®19 application from the first day of the disease, it is possible to reduce its duration by more than two-fold. Thus, the costs of medical care amount to 2,078 rubles. Payments for disability leaves by the Social Fund of Russia will amount to 2,287 rubles, and the lost GDP – 9,148 rubles (total costs 13,513 rubles).Conclusion. For the first time in Russian economic conditions, the use of IRS®19 for ARI treatment and prevention in children was evaluated. IRS®19 application from the first symptoms of the disease allows refusing the use of topical interferons, reduces the duration of symptoms and the need for prescription of antitussives, vasoconstrictors, and antibiotics. |
| format | Article |
| id | doaj-art-896992118f554131a5ad3c8148fc4d81 |
| institution | Kabale University |
| issn | 2070-4909 2070-4933 |
| language | Russian |
| publishDate | 2024-08-01 |
| publisher | IRBIS LLC |
| record_format | Article |
| series | Фармакоэкономика |
| spelling | doaj-art-896992118f554131a5ad3c8148fc4d812025-08-20T03:39:50ZrusIRBIS LLCФармакоэкономика2070-49092070-49332024-08-0117218219010.17749/2070-4909/farmakoekonomika.2024.244496Clinical and economic assessment of using IRS®19 for the treatment and prevention of acute respiratory infections in childrenA. S. Kolbin0A. R. Kasimova1Pavlov First Saint Petersburg State Medical University; Saint Petersburg State UniversityPavlov First Saint Petersburg State Medical University; Vreden National Medical Research Center of Traumatology and OrthopedicsObjective: to perform pharmacoeconomic analysis of the feasibility of using topical bacterial lysate in the form of nasal spray (IRS®19) for the treatment and prevention of upper respiratory tract infections in pediatric population in comparison with other drugs registered in Russia, belonging to the class of topical interferons.Material and methods. Based on the Rosstat data and information from open sources, the population of patients with acute respiratory infections (ARI) was calculated. Considering the Russian clinical recommendations “Acute respiratory viral infection (ARVI)” and “Acute tonsillitis and pharyngitis (acute tonsillopharyngitis)”, the direct medical costs of providing medical care to specialized patients were determined. Direct costs on the part of parents included all costs for purchasing medicines for basic or concomitant therapy. Direct costs on the part of the healthcare system and the state included the costs of providing medical care at the outpatient stage. Direct non-medical costs included payments for disability leaves, indirect costs – lost gross domestic product (GDP) due to absence from work.Results. The total costs of the healthcare system and the state for 1 AVI patient are 42,472 rubles in case of uncomplicated course and 70,649 rubles in case of complicated course. In case of IRS®19 application from the first day of the disease, it is possible to reduce its duration by more than two-fold. Thus, the costs of medical care amount to 2,078 rubles. Payments for disability leaves by the Social Fund of Russia will amount to 2,287 rubles, and the lost GDP – 9,148 rubles (total costs 13,513 rubles).Conclusion. For the first time in Russian economic conditions, the use of IRS®19 for ARI treatment and prevention in children was evaluated. IRS®19 application from the first symptoms of the disease allows refusing the use of topical interferons, reduces the duration of symptoms and the need for prescription of antitussives, vasoconstrictors, and antibiotics.https://www.pharmacoeconomics.ru/jour/article/view/1036acute respiratory infectionariupper respiratory tract infectiontopical bacterial lysateimmune defensenasal spraypharmacoeconomic analysis |
| spellingShingle | A. S. Kolbin A. R. Kasimova Clinical and economic assessment of using IRS®19 for the treatment and prevention of acute respiratory infections in children Фармакоэкономика acute respiratory infection ari upper respiratory tract infection topical bacterial lysate immune defense nasal spray pharmacoeconomic analysis |
| title | Clinical and economic assessment of using IRS®19 for the treatment and prevention of acute respiratory infections in children |
| title_full | Clinical and economic assessment of using IRS®19 for the treatment and prevention of acute respiratory infections in children |
| title_fullStr | Clinical and economic assessment of using IRS®19 for the treatment and prevention of acute respiratory infections in children |
| title_full_unstemmed | Clinical and economic assessment of using IRS®19 for the treatment and prevention of acute respiratory infections in children |
| title_short | Clinical and economic assessment of using IRS®19 for the treatment and prevention of acute respiratory infections in children |
| title_sort | clinical and economic assessment of using irs r 19 for the treatment and prevention of acute respiratory infections in children |
| topic | acute respiratory infection ari upper respiratory tract infection topical bacterial lysate immune defense nasal spray pharmacoeconomic analysis |
| url | https://www.pharmacoeconomics.ru/jour/article/view/1036 |
| work_keys_str_mv | AT askolbin clinicalandeconomicassessmentofusingirs19forthetreatmentandpreventionofacuterespiratoryinfectionsinchildren AT arkasimova clinicalandeconomicassessmentofusingirs19forthetreatmentandpreventionofacuterespiratoryinfectionsinchildren |